TCRX Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -2849.09% compared to TScan Therapeutics's net margin of 11.99%. TScan Therapeutics's return on equity of -60.03% beat Johnson & Johnson's return on equity of 20.88%.

TScan Therapeutics has a consensus price target of $12.14, signalling upside risk potential of 307.48%. On the other hand Johnson & Johnson has an analysts' consensus of $172.43 which suggests that it could grow by 20.03%. Given that TScan Therapeutics has higher upside potential than Johnson & Johnson, analysts believe TScan Therapeutics is more attractive than Johnson & Johnson.

TScan Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.514, suggesting its less volatile than the S&P 500 by 48.607%.

TScan Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.42% to investors and pays a quarterly dividend of $1.24 per share. TScan Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

TScan Therapeutics quarterly revenues are $1M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. TScan Therapeutics's net income of -$29.9M is lower than Johnson & Johnson's net income of $2.7B. Notably, TScan Therapeutics's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 23.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TScan Therapeutics is 33.60x versus 3.98x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

MultiPlan has a net margin of -2849.09% compared to TScan Therapeutics's net margin of -169.83%. TScan Therapeutics's return on equity of -60.03% beat MultiPlan's return on equity of -141.48%.

TScan Therapeutics has a consensus price target of $12.14, signalling upside risk potential of 307.48%. On the other hand MultiPlan has an analysts' consensus of $10.00 which suggests that it could fall by -19.68%. Given that TScan Therapeutics has higher upside potential than MultiPlan, analysts believe TScan Therapeutics is more attractive than MultiPlan.

TScan Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MultiPlan has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

TScan Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MultiPlan offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TScan Therapeutics pays -- of its earnings as a dividend. MultiPlan pays out -- of its earnings as a dividend.

TScan Therapeutics quarterly revenues are $1M, which are smaller than MultiPlan quarterly revenues of $230.5M. TScan Therapeutics's net income of -$29.9M is higher than MultiPlan's net income of -$391.5M. Notably, TScan Therapeutics's price-to-earnings ratio is -- while MultiPlan's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TScan Therapeutics is 33.60x versus 0.21x for MultiPlan. Usually stocks with elevated PS ratios are considered overvalued.

OS Therapies has a net margin of -2849.09% compared to TScan Therapeutics's net margin of --. TScan Therapeutics's return on equity of -60.03% beat OS Therapies's return on equity of --.

TScan Therapeutics has a consensus price target of $12.14, signalling upside risk potential of 307.48%. On the other hand OS Therapies has an analysts' consensus of $12.67 which suggests that it could grow by 159.1%. Given that TScan Therapeutics has higher upside potential than OS Therapies, analysts believe TScan Therapeutics is more attractive than OS Therapies.

TScan Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison OS Therapies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

TScan Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OS Therapies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TScan Therapeutics pays -- of its earnings as a dividend. OS Therapies pays out -- of its earnings as a dividend.

TScan Therapeutics quarterly revenues are $1M, which are larger than OS Therapies quarterly revenues of --. TScan Therapeutics's net income of -$29.9M is lower than OS Therapies's net income of -$2.9M. Notably, TScan Therapeutics's price-to-earnings ratio is -- while OS Therapies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TScan Therapeutics is 33.60x versus -- for OS Therapies. Usually stocks with elevated PS ratios are considered overvalued.

scPharmaceuticals has a net margin of -2849.09% compared to TScan Therapeutics's net margin of -350.14%. TScan Therapeutics's return on equity of -60.03% beat scPharmaceuticals's return on equity of -265.48%.

TScan Therapeutics has a consensus price target of $12.14, signalling upside risk potential of 307.48%. On the other hand scPharmaceuticals has an analysts' consensus of $17.50 which suggests that it could grow by 383.43%. Given that scPharmaceuticals has higher upside potential than TScan Therapeutics, analysts believe scPharmaceuticals is more attractive than TScan Therapeutics.

TScan Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison scPharmaceuticals has a beta of 0.111, suggesting its less volatile than the S&P 500 by 88.939%.

TScan Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. scPharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TScan Therapeutics pays -- of its earnings as a dividend. scPharmaceuticals pays out -- of its earnings as a dividend.

TScan Therapeutics quarterly revenues are $1M, which are smaller than scPharmaceuticals quarterly revenues of $10M. TScan Therapeutics's net income of -$29.9M is higher than scPharmaceuticals's net income of -$35.1M. Notably, TScan Therapeutics's price-to-earnings ratio is -- while scPharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TScan Therapeutics is 33.60x versus 4.88x for scPharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.